Breaking News on Biopharmaceutical Development & Manufacturing

Top Headlines

Dispatches from Interphex Japan

Tokyo drift? Large molecule R&D shortfall threat to Japanese pharma, says Chugai

A failure to embrace biologics R&D has restricted Japanese pharma’s global growth, says CEO of Roche subsidiary Chugai Pharmaceuticals.

Pfizer starts work on Missouri biotherapeutics R&D hub

Pfizer is building a $200m R&D centre in Chesterfield, Missouri at which it will consolidate biotherapeutics process development operations in the region.

Cloud-based platform for cell therapies to meet increased production levels

Vineti has developed a cloud-based software platform for creating and delivering cell and gene cell therapies, which the company says is better suited to high production loads than paper-driven processes.  

Repligen CEO says Spectrum acquisition fills gap in bioprocessing product line

Repligen Corporation has announced it will acquire filtration-focused Spectrum Pharmaceuticals for approximately $350m (€312m).

Lonza’s $5.5bn Capsugel takeover cleared by regulators

Lonza expects to complete its $5.5bn (€5.2bn) takeover of Capsugel SA in the next few days having secured approval from competition authorities around the world.

OSE Immunotherapeutics halts recruitment in cancer vaccine trial

OSE Immunotherapeutics SA has halted recruitment in a Phase III trial of its cancer vaccine Tedopi (OSE2101).

Key Industry Events


Access all events listing

Our events, Shows & Conferences...